May 15, 2018 / 12:39 PM / 11 days ago

BRIEF-Biomarin Announces First Patient Dosed In Phase 1/2 Study Of Treatment For Type of Hemophilia A

May 15 (Reuters) - Biomarin Pharmaceutical Inc:

* BIOMARIN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 STUDY EVALUATING VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY IN SEVERE HEMOPHILIA A PATIENTS WITH PRE-EXISTING AAV5 ANTIBODIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below